Ritonavir-boosted HIV protease inhibitors in first-line antiretroviral therapy regimens
- Authors: Kravchenko AV1, Kanestri VG1, Gankina NY.2, Kozyrev OA3, Ibragimova LE4, Khromova IY.5, Minayeva SV6
-
Affiliations:
- Federal Research and Methodological Center for AIDS Prevention and Control, Moscow
- Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases
- Volgograd Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Ulyanovsk Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Kaliningrad Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Issue: Vol 15, No 3 (2010)
- Pages: 22-27
- Section: Articles
- URL: https://rjeid.com/1560-9529/article/view/40452
- DOI: https://doi.org/10.17816/EID40452
- ID: 40452
Cite item
Full Text
Abstract
About the authors
A V Kravchenko
Federal Research and Methodological Center for AIDS Prevention and Control, Moscow
Email: kravtchenko@hivrussia.net
Federal Research and Methodological Center for AIDS Prevention and Control, Moscow
V G Kanestri
Federal Research and Methodological Center for AIDS Prevention and Control, MoscowFederal Research and Methodological Center for AIDS Prevention and Control, Moscow
N Yu Gankina
Krasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious DiseasesKrasnoyarsk Territorial Center for Prevention and Control of AIDS and Infectious Diseases
O A Kozyrev
Volgograd Regional Center for Prevention and Control of AIDS and Infectious DiseasesVolgograd Regional Center for Prevention and Control of AIDS and Infectious Diseases
L E Ibragimova
Ulyanovsk Regional Center for Prevention and Control of AIDS and Infectious DiseasesUlyanovsk Regional Center for Prevention and Control of AIDS and Infectious Diseases
I Ye Khromova
Kaliningrad Regional Center for Prevention and Control of AIDS and Infectious DiseasesKaliningrad Regional Center for Prevention and Control of AIDS and Infectious Diseases
S V Minayeva
Nizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious DiseasesNizhni Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases
References
- Клинические рекомендации. ВИЧ-инфекция и СПИД / Под ред. В. В. Покровского. - М., 2006.
- Кравченко А. В., Ситдыкова Ю. Р., Серебровская Л. В. и др. Комбинированная антиретровирусная терапия больных ВИЧ-инфекцией с использованием "усиленных" ингибиторов протеазы ВИЧ // Инфекц. бол. - 2003. - Т. 1, № 1. - С. 14-19.
- Кравченко А. В., Беляева В. В., Ситдыкова Ю. Р. и др. Факторы, определяющие эффективность высокоактивной антиретровирусной терапии у больных ВИЧ-инфекцией // Эпидемиол. и инфекц. бол. - 2005. - № 5. - С. 53-58.
- Кравченко А. В., Салит И., Беляева В. В. и др. Влияние приверженности лечению на эффективность высокоактивной антиретровирусной терапии у взрослых больных инфекцией ВИЧ // Фарматека. - 2005. - № 19. - С. 81-85.
- Кравченко А. В. Современные подходы к началу высокоактивной антиретровирусной терапии и выбор оптимальной схемы лечения первой линии // Фарматека. - 2008. - № 19. - С.79-83.
- Кравченко А. В., Юрин О. Г., Беляева В. В., Покровский В. В. Лечение ВИЧ-инфекции, вызываемой вирусом иммунодефицита человека, в Российской Федерации // Тер. арх. - 2009. - Т.81, № 4. - С. 64-69.
- European AIDS Clinical Society Issues New Guidelines for Treatment of HIV. October, 2008 (http://www.hivandhepatitis.com).
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents // Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) November 3, 2008 (http://AIDSinfo.nih.gov).
- Hammer S. M., Eron J. J., Reiss P. et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel // J. A. M. A. - 2008. - Vol. 300. - P. 555-570.
- Mills A., Nelson M., Jayaweera D. et al. ARTEMIS: Efficacy and safety of darunavi/ritonavir (DRV/r) 800/100 mg once-daily vs lopinavir/ritonavir (LPV/r) in treatment-naive, HIV-1-infected patients at 96 Wks // 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008). Washington, DC. Oct. 25-28, 2008. - Washington, 2008. Abstr. H-1250c.
- Molina J. M., Andrare-Villanueva J., Echevarria J. et al. Atazanavir/ritonavir vs lopinavir/ritonavir in antiretroviral-naive HIV-1-infected patients: CASTLE 96 week efficacy and safety // Program and Abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting, Oct. 25-28, 2008, Washington, DC. - Washington, 2008. - Abstr. H-1250d.
- Pulido F., Baril J. G., Staszewski S. et al. Long-term efficacy and safety of fosamprenavir + ritonavir (FPV/r) versus lopinavir/ ritonavir (LPV/r) over 96 weeks // 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2007). Chicago, Sept. 17-20, 2007. - Chicago, 2007. - Abstr. H-361.